Literature DB >> 20505644

Pazopanib in renal cell carcinoma.

Cora N Sternberg1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505644

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  6 in total

1.  Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.

Authors:  Amber Kempton; Cody Justice; Aaron Guo; Matthew Cefalu; Michael Makara; Paul Janssen; Thai H Ho; Sakima A Smith
Journal:  Clin Exp Hypertens       Date:  2017-11-27       Impact factor: 1.749

2.  Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Authors:  Sebastien J Hotte; Anil Kapoor; Naveen S Basappa; Georg Bjarnason; Christina Canil; Henry J Conter; Piotr Czaykowski; Jeffrey Graham; Samantha Gray; Daniel Y C Heng; Pierre I Karakiewicz; Christian Kollmannsberger; Aly-Khan A Lalani; Scott A North; François Patenaude; Denis Soulières; Phillippe Violette; Eric Winquist; Lori A Wood; Shaan Dudani; Ranjena Maloni; M Neil Reaume
Journal:  Can Urol Assoc J       Date:  2019-10       Impact factor: 1.862

3.  Pazopanib for the treatment of patients with advanced renal cell carcinoma.

Authors:  Joshua M Lang; Michael R Harrison
Journal:  Clin Med Insights Oncol       Date:  2010-10-01

4.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Authors:  M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

Review 5.  A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.

Authors:  Z Mihaly; Z Sztupinszki; P Surowiak; B Gyorffy
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

6.  Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.

Authors:  Daniel Pinkhas; Thai Ho; Sakima Smith
Journal:  Cardiooncology       Date:  2017-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.